Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 7/2016

01-07-2016 | Urology - Original Paper

Circulating microRNAs as novel biomarkers in the diagnosis of prostate cancer: a systematic review and meta-analysis

Authors: Changqing Yin, Cheng Fang, Hong Weng, Chunhui Yuan, Fubing Wang

Published in: International Urology and Nephrology | Issue 7/2016

Login to get access

Abstract

Background

The diagnostic value of circulating microRNAs (miRNAs) detection in prostate cancer (PC) patients is currently under debate. Thus, we performed this meta-analysis of published literature to systematically evaluate the diagnostic potential of circulating miRNAs in PC.

Methods

Eligible studies were searched in PubMed, Embase and Chinese National Knowledge Infrastructure databases. Sensitivity and specificity were pooled using a random-effects model and were used to plot the summary receiver operator characteristic (SROC) curve. All analyses were performed using the Stata 13.0 software and Meta-Disc 1.4 for windows.

Results

A total of ten articles were included for the meta-analysis according to the inclusion criteria. The pooled results based on all included studies showed circulating miRNAs have a relatively good diagnostic performance, with a sensitivity of 0.74, a specificity of 0.71 and an area under SROC curve (AUC) of 0.77 in indiscriminating PC from controls. Furthermore, meta-regression and subgroup analyses indicate that multiple circulating miRNAs detection displayed a better diagnostic performance than single one, with an AUC rising from 0.75 to 0.81. Additional interesting finding was that Caucasian-based circulating miRNAs assays could reach a higher accuracy compared with non-Caucasian-based one for PC with the p value of 0.0378.

Conclusion

Our results confirmed the potential use of circulating miRNAs in the early diagnosis of PC, especially the combination of multiple circulating miRNAs. However, large-scale prospective studies are still needed to further validate our findings.
Literature
1.
2.
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215–224CrossRefPubMed
3.
Dall’Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L et al (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112(8):1650–1659CrossRefPubMed
4.
Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20(5):515–524CrossRefPubMed
5.
Inui M, Martello G, Piccolo S (2010) MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 11(4):252–263CrossRefPubMed
6.
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006CrossRefPubMed
7.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99(24):15524–15529CrossRefPubMedPubMedCentral
8.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065–7070CrossRefPubMed
9.
Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS et al (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58(10):1375–1381CrossRefPubMed
10.
Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP, Meese E (2009) miRNAs in lung cancer—studying complex fingerprints in patient’s blood cells by microarray experiments. BMC Cancer 9:353CrossRefPubMedPubMedCentral
11.
Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY et al (2010) Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70(23):9798–9807CrossRefPubMed
12.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518CrossRefPubMedPubMedCentral
13.
Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J (2011) Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77(5):1265–1269CrossRefPubMed
14.
Yaman AF, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, Gezer U (2011) Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32(3):583–588CrossRef
15.
Zhang HL, Qin XJ, Cao DL, Zhu Y, Yao XD, Zhang SL, Dai B, Ye DW (2013) An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl 15(2):231–235CrossRefPubMedPubMedCentral
16.
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536CrossRefPubMed
17.
Walter SD (2002) Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 21(9):1237–1256CrossRefPubMed
18.
19.
Dinnes J, Deeks J, Kirby J, Roderick P (2005) A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 9(12):1–113CrossRef
20.
Jackson D, White IR, Thompson SG (2010) Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat Med 29(12):1282–1297CrossRefPubMed
21.
Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58(9):882–893CrossRefPubMed
22.
Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, Christova S, Mitev V et al (2015) Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol 34(3):189–200CrossRefPubMedPubMedCentral
23.
Srivastava A, Goldberger H, Dimtchev A, Marian C, Soldin O, Li X, Collins SP, Suy S et al (2014) Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumour Biol 35(5):4867–4873CrossRefPubMedPubMedCentral
24.
Kotb S, Mosharafa A, Essawi M, Hassan H, Meshref A, Morsy A (2014) Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer. Tumour Biol 35(12):12613–12617CrossRefPubMed
25.
Egidi MG, Cochetti G, Serva MR, Guelfi G, Zampini D, Mechelli L, Mearini E (2013) Circulating microRNAs and kallikreins before and after radical prostatectomy: are they really prostate cancer markers? BioMed Res Int 2013:241780CrossRefPubMedPubMedCentral
26.
Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, Yang J (2012) A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 72(13):1443–1452CrossRefPubMed
27.
Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T et al (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106(4):768–774CrossRefPubMedPubMedCentral
28.
Liao YF, Dai JH, Mao QF (2014) Circulating miRNA-141 as a non-invasive biomarker for prostate cancer detection and prognosis. Chin J Pathol 30(10):1887–1890
29.
Papagiannakopoulos T, Shapiro A, Kosik KS (2008) MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68(19):8164–8172CrossRefPubMed
30.
Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27(31):4373–4379CrossRefPubMed
31.
Yang Q, Zheng Y, Zhu D (2014) Diagnostic performance of microRNAs expression in prostate cancer. Tumour Biol 35(10):10529–10538CrossRefPubMed
Metadata
Title
Circulating microRNAs as novel biomarkers in the diagnosis of prostate cancer: a systematic review and meta-analysis
Authors
Changqing Yin
Cheng Fang
Hong Weng
Chunhui Yuan
Fubing Wang
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 7/2016
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-016-1281-4

Other articles of this Issue 7/2016

International Urology and Nephrology 7/2016 Go to the issue

Nephrology - Original Paper

The impact of stage of chronic kidney disease on the outcomes of diabetics with acute myocardial infarction treated with percutaneous coronary intervention

Urology - Original Paper

Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study

Urology - Original Paper

Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy

Urology - Original Paper

Insertion of a single double-J stent for bilateral open ureteral reimplantation: introducing a novel technique and assessment of feasibility

Urology - Review

Focusing on organ preservation and function: paradigm shifts in the treatment of pediatric genitourinary rhabdomyosarcoma

Nephrology – Review

Glomerular filtration rate equations: a comprehensive review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits